Oral Antiviral Use Reduces COVID-19 Risk

Nirmatrelvir plus ritonavir reduces health risk
oral antiviral
by Miguel Á. Padriñán
Boston (Coronavirus Today)

The journal Annals of Internal Medicines published Original Research today that concluded the overall risk for hospitalization, or death was already low (1%) after an outpatient diagnosis of COVID-19, but administering Nirmatrelvir plus Ritonavir reduced the health risk even further.

The results of this study were published on December 13, 2022.

The U.S. National Institutes of Health-funded study assessed whether nirmatrelvir plus ritonavir reduces the risk of hospitalization or death among outpatients with early COVID-19 in the setting of overall SARS-CoV-2 immunity and immune-evasive SARS-CoV-2 lineages.

During the study period, 12,541 (28.1%) patients were prescribed nirmatrelvir plus ritonavir, and 32,010 (71.9%) were not.

Patients prescribed nirmatrelvir plus ritonavir were more likely to be older, have more comorbidities, and be COVID-19 vaccinated.

The composite outcome of hospitalization or death occurred in (0.55%) of patients who were prescribed nirmatrelvir plus ritonavir and (0.97%) who were not (adjusted risk ratio, 0.56 [95% CI, 0.42 to 0.75]).

Furthermore, the recipients of nirmatrelvir plus ritonavir had a lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]).

The researchers concluded the use of nirmatrelvir plus ritonavir could reduce health risks.

The nirmatrelvir plus ritonavir combination is known as Paxlovid™ and is U.S. FDA-Approved.

Paxlovid works intracellularly, binding to the highly conserved main protease of SARS-CoV-2 coronavirus.

By inhibiting the main protease, it inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In the U.S., Paxlovid is available at most pharmacies.

Other COVID-19 treatment news is posted at CoronavirusToday.com/Antiviruals

CoronavirusToday publishes fact-checked, research-based information manually curated for mobile readers.

Article by
Donald Hackett